Classification Term: 3450

Benzanilides (ontology term: CHEMONTID:0004713)

found 62 associated metabolites at family metabolite taxonomy ontology rank level.

Ancestor: Aromatic anilides

Child Taxonomies: There is no child term of current ontology term.

Benzoylprop-ethyl

ethyl 2-[N-(3,4-dichlorophenyl)-1-phenylformamido]propanoate

C18H17Cl2NO3 (365.0585)


   

Encainide

(+-)-4-Methoxy-N-(2-(2-(1-methyl-2-piperidinyl)ethyl)phenyl)benzamide

C22H28N2O2 (352.2151)


All drug products containing encainide hydrochloride. Encainide hydrochloride, formerly marketed as Enkaid capsules, was associated with increased death rates in patients who had asymptomatic heart rhythm abnormalities after a recent heart attack. The manufacturer of Enkaid capsules voluntarily withdrew the product from the US market on December 16, 1991. C - Cardiovascular system > C01 - Cardiac therapy > C01B - Antiarrhythmics, class i and iii > C01BC - Antiarrhythmics, class ic D002317 - Cardiovascular Agents > D026941 - Sodium Channel Blockers > D061567 - Voltage-Gated Sodium Channel Blockers C78274 - Agent Affecting Cardiovascular System > C47793 - Antiarrhythmic Agent D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents D049990 - Membrane Transport Modulators C93038 - Cation Channel Blocker

   

Phthalylsulfathiazole

2-[[[4-[(2-Thiazolylamino)sulphonyl]phenyl]amino]carbonyl]benzoic acid

C17H13N3O5S2 (403.0297)


A - Alimentary tract and metabolism > A07 - Antidiarrheals, intestinal antiinflammatory/antiinfective agents > A07A - Intestinal antiinfectives > A07AB - Sulfonamides C254 - Anti-Infective Agent > C29739 - Sulfonamide Anti-Infective Agent D000890 - Anti-Infective Agents > D013432 - Sulfathiazoles D000890 - Anti-Infective Agents > D013424 - Sulfanilamides

   

Suramin

8-{4-methyl-3-[3-({[3-({2-methyl-5-[(4,6,8-trisulfonaphthalen-1-yl)carbamoyl]phenyl}carbamoyl)phenyl]carbamoyl}amino)benzamido]benzamido}naphthalene-1,3,5-trisulfonic acid

C51H40N6O23S6 (1296.0469)


A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties. Suramin is manufactured by Bayer in Germany as Germanin®. C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor > C1971 - Angiogenesis Activator Inhibitor D000890 - Anti-Infective Agents > D000977 - Antiparasitic Agents > D000981 - Antiprotozoal Agents D000890 - Anti-Infective Agents > D000977 - Antiparasitic Agents > D000871 - Anthelmintics D000970 - Antineoplastic Agents

   

Ameltolide

4-Amino-N-(2,6-dimethylphenyl)benzamide

C15H16N2O (240.1263)


C78272 - Agent Affecting Nervous System > C264 - Anticonvulsant Agent Same as: D02892

   

Salicylanilide

2-hydroxy-N-phenylbenzene-1-carboximidic acid

C13H11NO2 (213.079)


CONFIDENCE standard compound; INTERNAL_ID 1155; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8893; ORIGINAL_PRECURSOR_SCAN_NO 8889 CONFIDENCE standard compound; INTERNAL_ID 1155; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4519; ORIGINAL_PRECURSOR_SCAN_NO 4518 CONFIDENCE standard compound; INTERNAL_ID 1155; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4485; ORIGINAL_PRECURSOR_SCAN_NO 4483 CONFIDENCE standard compound; INTERNAL_ID 1155; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4501; ORIGINAL_PRECURSOR_SCAN_NO 4498 CONFIDENCE standard compound; INTERNAL_ID 1155; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4511; ORIGINAL_PRECURSOR_SCAN_NO 4507 CONFIDENCE standard compound; INTERNAL_ID 1155; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8917; ORIGINAL_PRECURSOR_SCAN_NO 8912 ORIGINAL_PRECURSOR_SCAN_NO 4498; CONFIDENCE standard compound; INTERNAL_ID 1155; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4501 CONFIDENCE standard compound; INTERNAL_ID 1155; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4478; ORIGINAL_PRECURSOR_SCAN_NO 4476 CONFIDENCE standard compound; INTERNAL_ID 1155; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4461; ORIGINAL_PRECURSOR_SCAN_NO 4458 C254 - Anti-Infective Agent > C28394 - Topical Anti-Infective Agent

   

Niclosamide

5-chloro-N-(2-chloro-4-nitrophenyl)-2-hydroxybenzamide

C13H8Cl2N2O4 (325.9861)


Niclosamide is used for the treatment of most tapeworm infections. Helminths (worms) are multicellular organisms that infect very large numbers of humans and cause a broad range of diseases. Over 1 billion people are infected with intestinal nematodes, and many millions are infected with filarial nematodes, flukes, and tapeworms. They are an even greater problem in domestic animals. P - Antiparasitic products, insecticides and repellents > P02 - Anthelmintics > P02D - Anticestodals > P02DA - Salicylic acid derivatives D000890 - Anti-Infective Agents > D000977 - Antiparasitic Agents > D000871 - Anthelmintics C254 - Anti-Infective Agent > C276 - Antiparasitic Agent > C250 - Antihelminthic Agent COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D010575 - Pesticides > D008975 - Molluscacides D016573 - Agrochemicals Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

   

Nilotinib

4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}benzamide

C28H22F3N7O (529.1838)


Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). In June 2006, a Phase I clinical trial found nilotinib has a relatively favorable safety profile and shows activity in cases of CML resistant to treatment with imatinib (Gleevec®), another tyrosine kinase inhibitor currently used as a first-line treatment. [Wikipedia] L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01EA - Bcr-abl tyrosine kinase inhibitors C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C164037 - PDGFR-targeting Agent C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163999 - cKIT-targeting Agent C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C159198 - c-KIT Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C155700 - BCR-ABL Inhibitor

   

3-O-Caffeoyl-4-O-methylquinic acid

1,3,4-trihydroxy-5-{[(2Z)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoyl]oxy}cyclohexane-1-carboxylic acid

C17H20O9 (368.1107)


3-O-Caffeoyl-4-O-methylquinic acid is found in green vegetables. It is a constituent of Phyllostachys edulis (moso bamboo). Constituent of Phyllostachys edulis (moso bamboo). 3-O-Caffeoyl-4-O-methylquinic acid is found in green vegetables. 3-Feruloylquinic acid, a derivative of quinic acid-bound phenolic acid, shows antioxidant activity. 3-Feruloylquinic acid markedly enhances by high photosynthetically active radiation (PAR) and UV irradiances[1][2]. 3-Feruloylquinic acid, a derivative of quinic acid-bound phenolic acid, shows antioxidant activity. 3-Feruloylquinic acid markedly enhances by high photosynthetically active radiation (PAR) and UV irradiances[1][2].

   

Carotamine

2-amino-4-(4-aminobenzoylamino)Benzoic acid

C14H13N3O3 (271.0957)


Carotamine is found in root vegetables. Carotamine is isolated from carrots. Isolated from carrots. Carotamine is found in root vegetables.

   

N-desmethylimatinib

N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)-4-(piperazin-1-ylmethyl)benzamide

C28H29N7O (479.2433)


N-Desmethylimatinib, also called CGP74588, is a metabolite of Imatinib, a tyrosine kinase inhibitor, which is used to treat chronic myelogenous leukemia (CML) with BCR-ABL activity, gastrointestinal stromal tumors and acute lymphocytic leukemia (ALL). N-desmethylimatinib is pharmacologically active and shows a similar potency and selectivity profile as the parent drug. In particular, it shows potent inhibition of BCR-ABL in the nanomolar range (PMID: 21225261). The N-demethylation of Imatinib to N-desmethylimatinib is done via the liver cytochrome P450 enzymes CYP2C8, CYP3A4, CYP3A5 and CYP3A7 (PMID: 20977456). N-desmethylimatinib is only found in individuals who have consumed or received the drug Imatinib.

   

CGP71422

1-methyl-4-({4-[(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)carbamoyl]phenyl}methyl)piperazin-1-ium-1-olate

C29H31N7O2 (509.2539)


CGP71422, also call Imatinib (Piperazine)-4-oxide, is a cytochrome P450 (CYP2D6) metabolite of Imatinib and belongs to the family of compounds known as 2-phenyl amino pyrimidine derivatives. Imatinib is a tyrosine kinase inhibitor, which is used to treat chronic myelogenous leukemia (CML) with BCR-ABL activity, gastrointestinal stromal tumors and acute lymphocytic leukemia (ALL). CGP71422, is only found in individuals who have consumed or received the drug Imatinib.

   

CGP72383

C29H33N7O2 (511.2696)


CGP72383 is a metabolite of Imatinib. Cgp72383 belongs to the family of Acyclic Alkanes. These are acyclic hydrocarbons consisting only of n carbon atoms and m hydrogen atoms where m=2*n + 2.

   

Conivaptan

(1,1-Biphenyl)-2-carboxamide, N-(4-((4,5-dihydro-2-methylimidazo(4,5-D)(1)benzazepin-6(1H)-yl)carbonyl)phenyl)-, monohydrochloride

C32H26N4O2 (498.2056)


Conivaptan is only found in individuals that have used or taken this drug. It is a non-peptide inhibitor of antidiuretic hormone (vasopressin). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH). Conivaptan inhibits both isotypes of the vasopressin receptor (V1a and V2).Conivaptan is a dual AVP antagonist with nanomolar affinity for human arginine vasopressin V1A and V2 receptors in vitro. This antagonism occurs in the renal collecting ducts, resulting in aquaresis, or excretion of free water. C - Cardiovascular system > C03 - Diuretics > C03X - Other diuretics > C03XA - Vasopressin antagonists C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist > C2180 - Vasopressin Antagonist D045283 - Natriuretic Agents > D065092 - Antidiuretic Hormone Receptor Antagonists D002317 - Cardiovascular Agents > D045283 - Natriuretic Agents

   

Bafetinib

N-[3-({[4,5-bipyrimidine]-2-yl}amino)-4-methylphenyl]-4-{[(3S)-3-(dimethylamino)pyrrolidin-1-yl]methyl}-3-(trifluoromethyl)benzamide

C30H31F3N8O (576.2573)


Bafetinib is a tyrosine kinase inhibitor used to treat chronic myelogenous leukemia (CML), a cancer characterized by increased and unregulated growth of white blood cells in the bone marrow and the accumulation of these cells in the blood. Bafetinib is able to bind ABL with greater affinity than Imatinib (25-55 times more potent). It is therefore administered to patients with Imatinib resistance. Notably, Bafetinib is ineffective against the T315I mutation in BCR-ABL, and further research is necessary. C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors

   

Ponatinib

3-(2-(imidazo(1,2-b)Pyridazin-3-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-y-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide

C29H27F3N6O (532.2198)


Ponatinib is a Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012 (DB08901). L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01EA - Bcr-abl tyrosine kinase inhibitors C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor > C93259 - VEGFR Tyrosine Kinase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163790 - Flt-3-targeting Agent C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163953 - VEGFR-targeting Agent C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C164037 - PDGFR-targeting Agent C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163999 - cKIT-targeting Agent C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C159198 - c-KIT Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C164035 - FGFR-targeting Agent C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C155727 - FGFR Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C159438 - RET Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C155700 - BCR-ABL Inhibitor D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors D000970 - Antineoplastic Agents

   

Tacedinaline

4-(Acetylamino)-N-(2-aminophenyl)benzamide

C15H15N3O2 (269.1164)


D004791 - Enzyme Inhibitors > D056572 - Histone Deacetylase Inhibitors C471 - Enzyme Inhibitor > C1946 - Histone Deacetylase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent D000970 - Antineoplastic Agents

   

N-(4-Amino-2,5-diethoxyphenyl)benzamide

N-(4-amino-2,5-diethoxyphenyl)benzenecarboximidic acid

C17H20N2O3 (300.1474)


   

2'-Methyl-4'-(5-methyl-(1,2,4)-oxadiazol-3-yl)biphenyl-4-carboxylic acid (4-methoxy-3-(4-methylpiperazin-1-yl)phenyl)amide

2-Methyl-4-(5-methyl-(1,2,4)-oxadiazol-3-yl)biphenyl-4-carboxylic acid (4-methoxy-3-(4-methylpiperazin-1-yl)phenyl)amide

C29H31N5O3 (497.2427)


D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D012702 - Serotonin Antagonists

   

Phthalanilic acid, 2',3'-dimethyl-

Benzoic acid,2-[[(2,3-dimethylphenyl)amino]carbonyl]-

C16H15NO3 (269.1052)


   

3-Amino-4-methoxybenzanilide

3-amino-4-methoxy-N-phenylbenzene-1-carboximidic acid

C14H14N2O2 (242.1055)


   

3,3',4',5-Tetrachlorosalicylanilide

3,5-dichloro-N-(3,4-dichlorophenyl)-2-hydroxybenzene-1-carboximidic acid

C13H7Cl4NO2 (348.9231)


D004791 - Enzyme Inhibitors

   

4-Fluoranyl-3-(4-Oxidanylpiperidin-1-Yl)sulfonyl-~{n}-[3,4,5-Tris(Fluoranyl)phenyl]benzamide

4-Fluoranyl-3-(4-oxidanylpiperidin-1-yl)sulphonyl-~{n}-[3,4,5-tris(fluoranyl)phenyl]benzamide

C18H16F4N2O4S (432.0767)


   

4-Tert-butyl-N-methyl-N-phenylbenzamide

Antigens, leukemia, common acute lymphoblastic

C18H21NO (267.1623)


   

N-(4-Amino-5-methoxy-2-methylphenyl)benzamide

Benzamide,N-(4-amino-5-methoxy-2-methylphenyl)-

C15H16N2O2 (256.1212)


   

4-Hydroxy-N-phenyl-3,5-bis(1-pyrrolidinylmethyl)benzamide

4-hydroxy-N-phenyl-3,5-bis[(pyrrolidin-1-yl)methyl]benzamide

C23H29N3O2 (379.226)


   

Andolast

4-(2H-1,2,3,4-tetrazol-5-yl)-N-[4-(2H-1,2,3,4-tetrazol-5-yl)phenyl]benzamide

C15H11N9O (333.1087)


C78273 - Agent Affecting Respiratory System > C29712 - Anti-asthmatic Agent > C319 - Bronchodilator

   

B-Raf inhibitor

N-{4-[(4-ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}-4-methyl-3-({6-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)benzamide

C29H31F3N6O2 (552.246)


   

Benzanilide

N-phenylbenzenecarboximidic acid

C13H11NO (197.0841)


   

benzoylphenylurea

1-benzoyl-1-phenylurea

C14H12N2O2 (240.0899)


C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C273 - Antimitotic Agent

   

Betrixaban

N-(5-chloropyridin-2-yl)-2-[4-(N,N-dimethylcarbamimidoyl)benzamido]-5-methoxybenzamide

C23H22ClN5O3 (451.1411)


B - Blood and blood forming organs > B01 - Antithrombotic agents > B01A - Antithrombotic agents > B01AF - Direct factor xa inhibitors C78275 - Agent Affecting Blood or Body Fluid > C263 - Anticoagulant Agent > C173067 - Direct Factor Xa Inhibitor C78275 - Agent Affecting Blood or Body Fluid > C263 - Anticoagulant Agent > C180619 - Direct Oral Anticoagulant D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D015842 - Serine Proteinase Inhibitors D006401 - Hematologic Agents > D000925 - Anticoagulants > D000991 - Antithrombins

   

CXCR3 Antagonist 6c

4-[2-(3-chlorobenzamido)-4-{[2-(2,4-dichlorophenyl)ethyl]carbamoyl}phenyl]-N-ethyl-1,4-diazepane-1-carboxamide

C30H32Cl3N5O3 (615.1571)


   

2-[(4-Benzamidophenyl)sulfonylamino]acetic acid

2-[(4-Benzamidophenyl)sulphonylamino]acetic acid

C15H14N2O5S (334.0623)


   

N-[4-[(4As)-1,2,4,4a,5,11-hexahydro-[1,4]oxazino[3,4-c][1,4]benzodiazepine-6-carbonyl]-3-chlorophenyl]-2-phenylbenzamide

N-(3-chloro-4-{13-oxa-1,9-diazatricyclo[9.4.0.0^{3,8}]pentadeca-3,5,7-triene-9-carbonyl}phenyl)-[1,1-biphenyl]-2-carboxamide

C32H28ClN3O3 (537.1819)


   

Chidamide

N-(2-amino-5-fluorophenyl)-4-{[3-(pyridin-3-yl)prop-2-enamido]methyl}benzamide

C22H19FN4O2 (390.1492)


   

Darexaban

N-(2-Hydroxy-6-(4-methoxybenzamido)phenyl)-4-(4-methyl-1,4-diazepan-1-yl)benzamide

C27H30N4O4 (474.2267)


D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D015842 - Serine Proteinase Inhibitors D006401 - Hematologic Agents > D000925 - Anticoagulants > D000991 - Antithrombins C78275 - Agent Affecting Blood or Body Fluid > C29750 - Thrombolytic Agent

   

Dinaline

Benzamide,4-amino-N-(2-aminophenyl)-

C13H13N3O (227.1059)


C471 - Enzyme Inhibitor > C1946 - Histone Deacetylase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent

   

Entinostat

N-[[4-[(2-Aminoanilino)-oxomethyl]phenyl]methyl]carbamic acid 3-pyridinylmethyl ester

C21H20N4O3 (376.1535)


L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01X - Other antineoplastic agents > L01XH - Histone deacetylase (hdac) inhibitors D004791 - Enzyme Inhibitors > D056572 - Histone Deacetylase Inhibitors C471 - Enzyme Inhibitor > C1946 - Histone Deacetylase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent D000970 - Antineoplastic Agents

   

Flamprop-methyl

methyl 2-[N-(3-chloro-4-fluorophenyl)-1-phenylformamido]propanoate

C17H15ClFNO3 (335.0724)


   

Flubendiamide

2-{[4-(1,1,1,2,3,3,3-heptafluoropropan-2-yl)-2-methylphenyl]carbamoyl}-6-iodo-N-(1-methanesulfonyl-2-methylpropan-2-yl)benzene-1-carboximidic acid

C23H22F7IN2O4S (682.0233)


D010575 - Pesticides > D007306 - Insecticides D016573 - Agrochemicals

   

Granotapide

N-[2-(Dimethylcarbamoyl)-4-{2-[3-ethoxy-2-(ethoxycarbonyl)-3-oxo-2-phenylpropoxy]-2-oxoethyl}phenyl]-4-(trifluoromethyl)-[1,1-biphenyl]-2-carboximidate

C39H37F3N2O8 (718.2502)


C78276 - Agent Affecting Digestive System or Metabolism > C29703 - Antilipidemic Agent

   

N-(3,5-Bis(trifluoromethyl)phenyl)-5-chloro-2-hydroxybenzamide

N-[3,5-bis(trifluoromethyl)phenyl]-5-chloro-2-hydroxybenzamide

C15H8ClF6NO2 (383.0148)


   

Lotamilast

Methyl 4-({3-[6,7-dimethoxy-2-(methylimino)-1,2-dihydroquinazolin-4-yl]phenyl}carbamoyl)benzoic acid

C26H24N4O5 (472.1747)


   

Masitinib

N-(4-methyl-3-{[4-(pyridin-3-yl)-2,3-dihydro-1,3-thiazol-2-ylidene]amino}phenyl)-4-[(4-methylpiperazin-1-yl)methyl]benzamide

C28H30N6OS (498.2202)


L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials, PDB, Protein Data Bank C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

   

Mocetinostat

N-(2-aminophenyl)-4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzamide

C23H20N6O (396.1699)


D004791 - Enzyme Inhibitors > D056572 - Histone Deacetylase Inhibitors C471 - Enzyme Inhibitor > C1946 - Histone Deacetylase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent

   

Modecainide

4-hydroxy-3-methoxy-N-{2-[2-(1-methylpiperidin-2-yl)ethyl]phenyl}benzamide

C22H28N2O3 (368.21)


C78274 - Agent Affecting Cardiovascular System > C47793 - Antiarrhythmic Agent D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents

   

Mozavaptan

N-{4-[5-(dimethylamino)-2,3,4,5-tetrahydro-1H-1-benzazepine-1-carbonyl]phenyl}-2-methylbenzamide

C27H29N3O2 (427.226)


C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist > C2180 - Vasopressin Antagonist D045283 - Natriuretic Agents > D065092 - Antidiuretic Hormone Receptor Antagonists D002317 - Cardiovascular Agents > D045283 - Natriuretic Agents

   

N-[4-Chloro-3-(trifluoromethyl)phenyl]-2-ethoxybenzamide

N-[4-chloro-3-(trifluoromethyl)phenyl]-2-ethoxybenzamide

C16H13ClF3NO2 (343.0587)


D009676 - Noxae > D011042 - Poisons D007155 - Immunologic Factors

   

N-Demethylencainide

4-methoxy-N-{2-[2-(piperidin-2-yl)ethyl]phenyl}benzamide

C21H26N2O2 (338.1994)


   

N-[4-[(4-Ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-4-methyl-3-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)benzamide

N-{4-[(4-ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}-4-methyl-3-{1H-pyrrolo[2,3-b]pyridin-4-yloxy}benzamide

C29H30F3N5O2 (537.2351)


D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors

   

O-Demethylencainide

4-hydroxy-N-{2-[2-(1-methylpiperidin-2-yl)ethyl]phenyl}benzamide

C21H26N2O2 (338.1994)


D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents

   

Oxyclozanide

2,3,5-trichloro-N-(3,5-dichloro-2-hydroxyphenyl)-6-hydroxybenzene-1-carboximidic acid

C13H6Cl5NO3 (398.879)


   

Diethyl 2-(acetoxy(3-(dimethylcarbamoyl)-4-(4'-(trifluoromethyl)-[1,1'-biphenyl]-2-carboxamido)phenyl)methyl)-2-phenylmalonate

N-{4-[1-(acetyloxy)-3-ethoxy-2-(ethoxycarbonyl)-3-oxo-2-phenylpropyl]-2-(dimethylcarbamoyl)phenyl}-4-(trifluoromethyl)-[1,1-biphenyl]-2-carboximidate

C39H37F3N2O8 (718.2502)


   

Tert-butyl 4-[4-[(2-chloro-5-nitrobenzoyl)amino]phenyl]piperazine-1-carboxylate

N-(4-(4-Tert-butoxycarbonylpiperazin-1-yl)phenyl)-(2-chloro-5-nitrophenyl)carboxamide

C22H25ClN4O5 (460.1513)


   

N-(3,5-Dichloro-4-hydroxyphenyl)-2-hydroxybenzamide

N-(3,5-Dichloro-4-hydroxyphenyl)-3-hydroxybenzene-1-carboximidate

C13H9Cl2NO3 (296.9959)


   

Tariquidar

N-[2-({4-[2-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl]phenyl}carbamoyl)-4,5-dimethoxyphenyl]quinoline-3-carboxamide

C38H38N4O6 (646.2791)


C1744 - Multidrug Resistance Modulator

   

APD 791

3-Methoxy-N-[3-(1-methyl-1H-pyrazol-5-yl)-4-[2-(morpholin-4-yl)ethoxy]phenyl]benzene-1-carboximidate

C24H28N4O4 (436.211)


   

Vismodegib

2-chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]-4-methanesulfonylbenzamide

C19H14Cl2N2O3S (420.0102)


L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01X - Other antineoplastic agents > L01XJ - Hedgehog pathway inhibitors C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C188731 - Hedgehog Pathway Inhibitor C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor

   

Wander

2-chloro-N1,N4-bis[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]benzene-1,4-dicarboxamide

C26H23ClN6O2 (486.1571)


   

XIPAMIDE

4-Chloro-N-(2,6-dimethylphenyl)-2-hydroxy-5-sulphamoylbenzene-1-carboximidic acid

C15H15ClN2O4S (354.0441)


C - Cardiovascular system > C03 - Diuretics > C03B - Low-ceiling diuretics, excl. thiazides > C03BA - Sulfonamides, plain D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D002317 - Cardiovascular Agents > D045283 - Natriuretic Agents C78275 - Agent Affecting Blood or Body Fluid > C448 - Diuretic D045283 - Natriuretic Agents > D004232 - Diuretics

   

N-[4-({3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl}sulfamoyl)phenyl]-3-methoxy-4-methylbenzamide

N-[4-({3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl}sulphamoyl)phenyl]-3-methoxy-4-methylbenzamide

C31H29N5O6S (599.1838)


   

Sodium humate

N1,N4-bis[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]-2-methoxybenzene-1,4-dicarboxamide

C27H26N6O3 (482.2066)


It is used as a food additive .